Date of Abstract presentation11th December 2023IndicationsFollicular LymphomaAbstract Number984Abstract typeOral
ZYNLONTA stands as an innovative CD19-directed antibody-drug conjugate (ADC). Upon binding to a cell expressing CD19, ZYNLONTA undergoes internalization, releasing a pyrrolobenzodiazepine (PBD) payload by enzymatic processes within the cell.
The clinical trial is strategically designed to assess the combination's efficacy in patients with relapsed or refractory follicular lymphoma with ≥1 line of systemic therapy, and exhibit GELF criteria or experience disease progression within 24 months (POD24) before enrollment. The interim findings presente...
